Background: The pandemic of coronavirus disease (COVID-19) emerged as a fatal infection, especially in immunocompromised patients. Currently, this infection is managed with systemic corticosteroids. Co-infection of CO-VID-19 with opportunistic fungi is increasingly recognized.
Methods: We describe a case of rhino-cerebral mucormycosis 12 days following severe COVID-19 in a diabetic patient.
Results: He received 50 mg amphotericin B and surgical debridement. The patient's symptoms improved following medical and surgical intervention.
Conclusions: Mucormycosis is an uncommon but serious infection that complicates the course of severe COVID-19. Subjects with diabetes mellitus and multiple risk factors may be at a higher risk for developing mucormycosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7754/Clin.Lab.2022.220232 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of retinal sublayers in patients with systemic COVID-19 illness with varying degrees of severity.
Sci Rep
January 2025
Poostchi Ophthalmology Research Center, Department of Ophthalmology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
COVID-19 infection has been linked to ocular involvement, particularly retinal microvascular changes. Additionally, prolonged hypoxemia may affect retinal sublayers located within the retinal watershed zone. The aim of this study was to evaluate retinal and optic nerve OCT parameters in patients with COVID-19 illness of varying severity and compare them with controls.
View Article and Find Full Text PDFFABP4 as a therapeutic host target controlling SARS-CoV-2 infection.
EMBO Mol Med
January 2025
Sabri Ülker Center for Metabolic Research, Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Host metabolic fitness is a critical determinant of infectious disease outcomes. Obesity, aging, and other related metabolic disorders are recognized as high-risk disease modifiers for respiratory infections, including coronavirus infections, though the underlying mechanisms remain unknown. Our study highlights fatty acid-binding protein 4 (FABP4), a key regulator of metabolic dysfunction and inflammation, as a modulator of SARS-CoV-2 pathogenesis, correlating strongly with disease severity in COVID-19 patients.
View Article and Find Full Text PDFCOVID-19 infection and risk of adverse drug reactions: Cohort study.
Therapie
January 2025
Centre régional de pharmacovigilance, hôpital Nord, CHU de Saint-Étienne, 42055 Saint-Étienne cedex, France.
Aim: During coronavirus disease 2019 (COVID-19), the incidence rate of adverse drug reactions (ADRs) in hospitalized patients seemed higher than before the pandemic. Severe inflammation triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was cited as an explanation. We aimed to determine whether COVID-19 infection was associated with a higher risk of ADRs compared to other infectious diseases.
View Article and Find Full Text PDFTrends in certifications of overall vision impairment and that due to diabetic retinopathy/maculopathy in England and Wales, 2009/2010 to 2019/2020: a retrospective database analysis.
BMJ Open
January 2025
Diabetes Research Group, Swansea University, Swansea, UK.
Objectives: This study aims to report the trends in the certification of both sight impairment (SI) and severe sight impairment (SSI) in England and Wales during the period of 2010 to 2020, prior to the COVID-19 pandemic. The focus is on diabetic retinopathy/maculopathy as the key causative factor.
Design: Retrospective database analysis.
Lessons Learned From Characterizing Long COVID Among US Medicare Beneficiaries.
Pharmacoepidemiol Drug Saf
February 2025
Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
Purpose: To characterize long-term effects of COVID-19 among older adults (aged ≥ 65 years).
Methods: This retrospective descriptive study utilized Medicare Fee-for-Service beneficiaries' claims to characterize post-COVID condition diagnosis code usage, long COVID (defined as post-COVID condition diagnoses made ≥ 28 days after an initial COVID-19 diagnosis) incidence, patient demographics, and concurrent diagnoses.
Results: During April 1, 2020 to May 21, 2022, 193 691 (0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!